Borderline Resectable Pancreatic Adenocarcinoma
Oncology·MeSH: Pancreatic Neoplasms
1 drug in development·1 company·5 clinical trials
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| HRS-4642+AG+Nimotuzumab | Merus N.V. (MRUS) |
Frequently asked questions
How many drugs are in development for Borderline Resectable Pancreatic Adenocarcinoma?
BioSniper tracks 1 drug in development for Borderline Resectable Pancreatic Adenocarcinoma across 1 company.
How many clinical trials target Borderline Resectable Pancreatic Adenocarcinoma?
There are 5 clinical trials targeting Borderline Resectable Pancreatic Adenocarcinoma tracked by BioSniper.
Deep-dive into Borderline Resectable Pancreatic Adenocarcinoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis